Express News | Invivyd Shares Are Trading Higher After the Company Announced PEMGARDA Showed Protection Against Dominant COVID-19 Variants Including LP.8.1

BenzingaMar 5 08:51 ET

Invivyd Is Maintained at Buy by D. Boral Capital

Dow JonesMar 5 07:55 ET · Ratings

Invivyd Price Target Maintained With a $9.00/Share by D. Boral Capital

Dow JonesMar 5 07:55 ET · Ratings

Invivyd Analyst Ratings

BenzingaMar 5 07:44 ET · Ratings

Invivyd, Inc. Reports Positive In Vitro Neutralization Data for PEMGARDA Against Dominant SARS-CoV-2 Variant LP.8.1

Quiver QuantitativeMar 5 07:11 ET

Express News | Invivyd Inc: Pemivibart Antiviral Activity Remains Within Range of Expected Assay Variability Since Omicron Ba.2

ReutersMar 5 07:06 ET